Targeting CSF-1R represents an effective strategy in modulating inflammatory diseases
文献类型：期刊论文
| 作者 | Xiang, Caigui1,2; Li, Heng1,3; Tang, Wei1,2,3
|
| 刊名 | PHARMACOLOGICAL RESEARCH
 |
| 出版日期 | 2023 |
| 卷号 | 187页码:17 |
| ISSN号 | 1043-6618 |
| 关键词 | CSF-1R CSF-1 IL-34 Inflammatory diseases Myeloid cells |
| DOI | 10.1016/j.phrs.2022.106566 |
| 通讯作者 | Li, Heng(cpuliheng@gmail.com) ; Tang, Wei(tangwei@simm.ac.cn) |
| 英文摘要 | Colony-stimulating factor-1 receptor (CSF-1R), also known as FMS kinase, is a type I single transmembrane protein mainly expressed in myeloid cells, such as monocytes, macrophages, glial cells, and osteoclasts. The endogenous ligands, colony-stimulating factor-1 (CSF-1) and Interleukin-34 (IL-34), activate CSF-1R and downstream signaling pathways including PI3K-AKT, JAK-STATs, and MAPKs, and modulate the proliferation, differentiation, migration, and activation of target immune cells. Over the past decades, the promising therapeutic potential of CSF-1R signaling inhibition has been widely studied for decreasing immune suppression and escape in tumors, owing to depletion and reprogramming of tumor-associated macrophages. In addition, the excessive activation of CSF-1R in inflammatory diseases is consecutively uncovered in recent years, which may result in inflammation in bone, kidney, lung, liver and central nervous system. Agents against CSF-1R signaling have been increasingly investigated in preclinical or clinical studies for inflammatory diseases treatment. However, the pathological mechanism of CSF-1R in inflammation is indistinct and whether CSF-1R signaling can be identified as biomarkers remains controversial. With the background information aforementioned, this review focus on the dialectical roles of CSF-1R and its ligands in regulating innate immune cells and highlights various therapeutic implications of blocking CSF-1R signaling in inflammatory diseases. |
| WOS关键词 | COLONY-STIMULATING FACTOR ; PSORIATIC-ARTHRITIS PATIENTS ; FETAL-MATERNAL INTERFACE ; FACTOR-I CSF-1 ; FACTOR-1 RECEPTOR ; TYROSINE KINASE ; DENDRITIC CELLS ; SERUM INTERLEUKIN-34 ; RHEUMATOID-ARTHRITIS ; LANGERHANS CELLS |
| 资助项目 | Science and Technology Commission of Shanghai Municipality ; National Natural Science Foundation of China ; [21ZR1474900] ; [82273760] |
| WOS研究方向 | Pharmacology & Pharmacy |
| 语种 | 英语 |
| 出版者 | ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD |
| WOS记录号 | WOS:000913191000004 |
| 源URL | [http://119.78.100.183/handle/2S10ELR8/303561]  |
| 专题 | 中国科学院上海药物研究所 |
| 通讯作者 | Li, Heng; Tang, Wei |
| 作者单位 | 1.Chinese Acad Sci, Shanghai Inst Mat Med, Lab Antiinflammat & Immunopharmacol, Shanghai 201203, Peoples R China 2.Univ Chinese Acad Sci, Sch Pharm, Beijing 100049, Peoples R China 3.Chinese Acad Sci, Shanghai Inst Mat Med, Lab Antiinflammat & Immunopharmacol, Shanghai, Peoples R China |
| 推荐引用方式 GB/T 7714 | Xiang, Caigui,Li, Heng,Tang, Wei. Targeting CSF-1R represents an effective strategy in modulating inflammatory diseases[J]. PHARMACOLOGICAL RESEARCH,2023,187:17. |
| APA | Xiang, Caigui,Li, Heng,&Tang, Wei.(2023).Targeting CSF-1R represents an effective strategy in modulating inflammatory diseases.PHARMACOLOGICAL RESEARCH,187,17. |
| MLA | Xiang, Caigui,et al."Targeting CSF-1R represents an effective strategy in modulating inflammatory diseases".PHARMACOLOGICAL RESEARCH 187(2023):17. |
入库方式： OAI收割
来源：上海药物研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。